Gain Therapeutics (GANX) Net Income (2020 - 2026)

Gain Therapeutics has reported Net Income for 7 years, with the latest figure at -$4.7 million in Q2 2026.

• On a quarterly basis, Net Income rose 19.51% year-over-year to -$4.7 million in Q2 2026; TTM through Jun 2026 was -$18.4 million, a 12.98% increase from a year earlier, with the FY2025 full-year figure at -$18.4 million, up 19.64% from the prior year.
• Net Income was -$4.7 million for Q2 2026 at Gain Therapeutics, up from -$5.6 million in the prior quarter.
• The five-year high for Net Income was -$2.8 million in Q4 2025, with the low at -$8.1 million in Q2 2024.
• Average Net Income over 5 years is -$5.1 million, with a median of -$4.9 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Net Income sank 56.98% in 2023, then soared 55.44% in 2025.
• Over 5 years, Net Income stood at -$4.7 million in 2022, then retreated by 7.25% to -$5.0 million in 2023, then slipped by 25.32% to -$6.3 million in 2024, then soared by 55.44% to -$2.8 million in 2025, then plunged by 67.01% to -$4.7 million in 2026.
• The last three Net Income figures came in at -$4.7 million (Q2 2026), -$5.6 million (Q1 2026), and -$2.8 million (Q4 2025), per Business Quant data.